循环miRNAs在肺癌诊断和治疗中的研究进展

肺癌是全世界男性和女性癌症死亡的第一原因。尽管近些年对癌症信号通路的了解和在新的治疗方法开发上有了新进展，但是肺癌的不良预后和高复发率依然存在。循环miRNAs在许多实体瘤（如肺癌）中，可作为稳定表达的非侵入性诊断标志物。一些miRNAs异常可能与肿瘤细胞常规化疗的耐药性有关，影响着肿瘤细胞的药物敏感性。这些miRNAs的调控,通过使用miRNAs类似物,可以调节关键基因网络和信号通路,通过抑制肿瘤细胞增殖来提高抗癌治疗的疗效，增加药物敏感性。因此,miRNAs疗法提供了新的抗肿瘤方法:更有效的个性化治疗、提高药物疗效、预测不同抗癌药物的反应。本综述的目的是为肺癌循环miRNA提供一个作为潜在诊断生物标志物、大规模临床筛选诊断的可行性评估以及miRNAS抗癌耐药机制对肺癌的治疗的概述。最后，miRNA分析的局限性和潜在性需要今后进一步探索。

Progress in application of circulating miRNAs in diagnosis and treatment of lung cancer

Lung cancer is the first cause of cancer deaths all over the world between men and women.Despite progress in recent years,understanding the cancer signaling pathway and development of new treatment methods,non small cell lung cancer (NSCLC) of poor prognosis and high recurrence rate is still there.The circulating miRNAs in many solid tumors such as lung cancer,As a non-invasive diagnostic markers stable replication and expression.Some miRNAs impariment may be involved in drug resistance of tumor cells to conventional chemotherapy,effecting of drug sensitivity of tumor cells.The modulation of these miRNAs,using the miRNAs mimics,can repair the key gene networks and signaling pathway,to optimize the anticancer therapise by inhibiting the tumor cell proliferation,and can increasing the drug sensitivity.Therefore,miRNAs therapy offers an attractive anti-tumor method,a personalized treatment method of newer,more effective,improve drug efficacy,predict the different response to anticancer drugs.The purpose of this review is to provide a circulating markers of miRNAs lung cancer as a potential diagnosis of biological,feasibility evaluation of large-scale clinical screening diagnosis and anticancer drug resistance mechanism of miRNAS in lung cancer.Finally,limitations and potential of miRNA analysis needs further exploration.